Targets › CD371
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: the race on CD371, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | CD371-YSNVZ-IL-18 CAR T cells anti-CD371 CAR-T cell therapy with IL-18 | CD371 | Phase 1 | Refractory Acute Myeloid Leukemia | Dec 2027 |
Refractory Acute Myeloid Leukemia (1)
other (1)
Memorial Sloan Kettering Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.